Boston Scientific reports fourth-quarter and full-year 2025 results, citing double-digit sales growth and acquisitions

Strong quarterly finish caps a higher-growth year

Boston Scientific reported fourth-quarter 2025 net sales of $5.286 billion, up 15.9% from the prior-year period on a reported basis. The company said growth was 14.3% on an operational basis and 12.7% on an organic basis.

For the quarter, GAAP net income attributable to common stockholders was $672 million, or $0.45 per diluted share, compared with $566 million, or $0.38 per share, a year earlier. Adjusted earnings per share for the quarter were reported at $0.80, up from $0.70 in the prior-year period.

Full-year 2025: $20.074 billion in sales and higher earnings

For full-year 2025, Boston Scientific reported net sales of $20.074 billion, a 19.9% increase on a reported basis versus 2024. The company reported 19.2% operational growth and 15.8% organic growth for the year.

GAAP net income attributable to common stockholders for 2025 was $2.898 billion, or $1.94 per diluted share, compared with $1.853 billion, or $1.25 per share, in 2024. The company reported adjusted earnings per share of $3.06 for 2025, up from $2.51 a year earlier.

Segment and regional performance in the quarter

• MedSurg segment: 11.7% reported sales growth (10.2% operational; 6.5% organic).
• Cardiovascular segment: 18.2% reported sales growth (16.5% operational; 16.1% organic).
• United States: 17.0% reported and operational growth.
• EMEA: 12.4% reported growth and 4.8% operational growth; the company highlighted the 2025 discontinuation of worldwide sales of the ACURATE neo2 and ACURATE Prime aortic valve systems, which it said had generated about $50 million per quarter in prior-year global sales.
• Asia-Pacific: 15.2% reported growth (14.8% operational).
• Latin America and Canada: 15.9% reported growth (10.4% operational).

Regulatory clearances and trials highlighted

Among recent developments, the company said it received U.S. FDA approval and a CE mark for the FARAPOINT pulsed field ablation catheter, and began enrollment in the OPTIMIZE clinical trial using electrographic flow mapping technology with the FARAPULSE platform. It also reported completed enrollment in trials involving the WATCHMAN FLX Pro device and the SEISMIQ intravascular lithotripsy system, along with FDA clearance for the TheraSphere 360 management platform.

M&A activity expands positions in vascular and urology adjacencies

Boston Scientific also underscored a series of transactions. In January 2026, it announced agreements to acquire Penumbra in a cash-and-stock transaction valuing Penumbra at about $14.5 billion enterprise value, and Valencia Technologies, developer of the eCoin system for urge urinary incontinence; both transactions are subject to customary closing conditions. The company also reported completing the acquisition of Nalu Medical, adding a peripheral nerve stimulation system to its neuromodulation portfolio.

The company said it uses adjusted and other non-GAAP measures to evaluate underlying operational performance and provided reconciliations in accompanying schedules.